Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following indolent or aggressive B-cell non-Hodgkin's lymphoma (NHL) subtypes: * Grade 1-3 follicular lymphoma * Mantle cell lymphoma * Small lymphocytic lymphoma * Diffuse large B-cell lymphoma * Diffuse mixed cell lymphoma * Marginal zone lymphoma * Relapsed or refractory CD20-positive disease * Measurable disease * Must have received ≥ 1 but \< 4 prior standard chemotherapy regimens * No Burkitt's lymphoma or precursor B-lymphoblastic lymphoma * No CNS lymphoma PATIENT CHARACTERISTICS: Performance status * Karnofsky 60-100% Life expectancy * At least 6 months Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 75,000/mm\^3 * Hemoglobin \> 7 g/dL Hepatic * AST or ALT \< 2 times upper limit of normal (unless due to primary disease) * Bilirubin ≤ 2 mg/dL Renal * Creatinine ≤ 2.0 mg/dL Cardiovascular * LVEF ≥ 50% by MUGA and/or 2-D echocardiogram * No history of New York Heart Association class II-IV cardiac disease * No congestive heart failure Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No known HIV positivity * No uncontrolled active bacterial, viral, or fungal infection * No other serious disease that would preclude study participation * No other primary malignancy within the past 5 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy * Recovered from prior immunotherapy * Prior immunotherapy, including rituximab or other monoclonal antibody, allowed Chemotherapy * See Disease Characteristics * More than 4 weeks since prior chemotherapy and recovered * No prior doxorubicin (or equivalent anthracycline) at a cumulative dose \> 400 mg/m\^2 * No other concurrent chemotherapy Endocrine therapy * Nonsteroidal hormones for nonlymphoma-related conditions (e.g., insulin for diabetes) allowed * No concurrent corticosteroids except for a transient inflammatory reaction (i.e., skin rash or hives) Radiotherapy * Recovered from prior radiotherapy * No concurrent radiotherapy Surgery * More than 4 weeks since prior major surgery (other than diagnostic surgery) and recovered Other * No other concurrent antitumor agents * No other concurrent investigational agents